Summary of opinion: Rinvoq, 25/06/2026 Positive
Summary of opinion: Rinvoq, 25/06/2026 Positive
Opinion
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Rinvoq. The marketing authorisation holder for this medicinal product is Abbvie Deutschland GmbH & Co. KG.
The CHMP adopted a new indication as follows:
Alopecia areata
Rinvoq is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older (see section 5.1).
The previously authorised indications for Rinvoq remain unchanged and are described in the Summary of product characteristics (SmPC).
For information, on 25 June 2026, the CHMP also adopted a new indication for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy. Further details are provided in a dedicated summary of opinion available on the EMA website.
Detailed recommendations for the use of this product will be described in the updated SmPC, which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.
CHMP post-authorisation summary of positive opinion for Rinvoq (VR-0000312506)
Adopted
Reference Number:
EMADOC-1700519818-3215454
English (EN) (117.69 KB - PDF)
First published:
26/06/2026
View
Key facts
Name of medicine
Rinvoq
EMA product number
EMEA/H/C/004760
Active substance
upadacitinib
International non-proprietary name (INN) or common name
upadacitinib
Therapeutic area (MeSH)
- Arthritis, Rheumatoid
- Arthritis, Psoriatic
- Axial Spondyloarthritis
- Spondylitis, Ankylosing
- Giant Cell Arteritis
- Dermatitis, Atopic
- Colitis, Ulcerative
- Crohn Disease
Anatomical therapeutical chemical (ATC) code
L04AA44
Marketing authorisation holder
AbbVie Deutschland GmbH & Co. KG
Date of opinion
25/06/2026
Status
Positive
News on Rinvoq
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2026
26/06/2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 February 2025
28/02/2025
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20 - 23 February 2023
24/02/2023
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 23-26 January 2023
27/01/2023
EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders
28/10/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 June 2022
24/06/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 May 2022
20/05/2022
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022
11/02/2022
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 21-24 June 2021
25/06/2021
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 7-10 December 2020
11/12/2020
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 14-17 October 2019
18/10/2019
More information on Rinvoq
This page was last updated on
26/06/2026
Summary
On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for the medicinal product Rinvoq. The marketing authorisation holder for this medicinal product is Abbvie Deutschland GmbH & Co. KG. The CHMP adopted a new indication as follows: Alopecia areata Rinvoq is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older (see section 5.1). The previously authorised indications for Rinvoq remain unchanged and are described in the Summary of product characteristics (SmPC). For information, on 25 June 2026, the CHMP also adopted a new indication for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy. Further details are provided in a dedicated summary of opinion available on the EMA website. Detailed recommendations for the use of this product will be described in the updated SmPC, which will be published on the EMA website in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.